Travere Therapeutics (TVTX) Expected to Announce Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) will likely be announcing its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.08. Travere Therapeutics had a negative return on equity of 1,179.73% and a negative net margin of 82.88%. The business had revenue of $81.73 million for the quarter, compared to the consensus estimate of $77.44 million. During the same quarter in the previous year, the business earned ($1.76) earnings per share. Travere Therapeutics’s quarterly revenue was up 83.3% on a year-over-year basis. On average, analysts expect Travere Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Travere Therapeutics Stock Performance

TVTX opened at $15.48 on Thursday. The business’s 50-day simple moving average is $15.32 and its 200 day simple moving average is $17.89. Travere Therapeutics has a 52-week low of $7.93 and a 52-week high of $25.29. The company has a debt-to-equity ratio of 9.46, a quick ratio of 2.03 and a current ratio of 2.05. The firm has a market capitalization of $1.37 billion, a PE ratio of -5.51 and a beta of 0.72.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Guggenheim reaffirmed a “buy” rating and set a $47.00 price target on shares of Travere Therapeutics in a research report on Monday, April 14th. Scotiabank restated an “outperform” rating on shares of Travere Therapeutics in a report on Friday, April 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Travere Therapeutics in a research report on Wednesday, April 23rd. Canaccord Genuity Group increased their price target on shares of Travere Therapeutics from $45.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, April 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, July 1st. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $32.14.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, CEO Eric M. Dube sold 18,924 shares of the firm’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $398,350.20. Following the completion of the sale, the chief executive officer directly owned 419,173 shares in the company, valued at $8,823,591.65. This trade represents a 4.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Christopher R. Cline sold 1,784 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $37,553.20. Following the sale, the chief financial officer owned 93,126 shares of the company’s stock, valued at approximately $1,960,302.30. This represents a 1.88% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,294 shares of company stock worth $485,123. 4.19% of the stock is owned by insiders.

Hedge Funds Weigh In On Travere Therapeutics

An institutional investor recently raised its position in Travere Therapeutics stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 13.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 56,777 shares of the company’s stock after purchasing an additional 6,831 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.06% of Travere Therapeutics worth $1,029,000 at the end of the most recent reporting period.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.